Hi Tony, I wrote that "clinical trials may be possible within a relatively short time frame".
The CD40L program has been a work-in-progress which has generated considerable data both in vitro and in vivo. The advice from management posted in a previous thread has been extremely useful in understanding both history and process. The rationale for believing that the lead phylomer candidates could be fast tracked is in part based upon the request by unknown parties - presumably Big Pharma - for additional in vitro data on benchmarks which compete with "the new generation of anti-CD40L therapies that have recently entered Phase I/II clinical trial[s]".
The new generation therapies are undoubtedly a reference to Biogen/UCBs clinical trials for systemic lupus erythematosus and amyotrophic lateral sclerosis. It would appear that a number of Big Pharma companies are looking to quickly follow Biogen/UCB into clinical trials with phylomer peptides which offer a 'competitive advantage' in targeting CD40L.
Regards,
Wayne.
PYC Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)